Nuvelo To Consider In-Licensing Deals In Wake Of Negative Alfimeprase Data
This article was originally published in The Pink Sheet Daily
Executive Summary
The firm halts enrollment of trials of the thrombolytic pending further review by outside experts and monitoring board.